Comments on ‘High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis’

Qu, Kunpeng; Gao, Peng; Si, Ruohuang

doi:10.3109/0284186x.2013.764012

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients must be followed by at least two postoperative investigations to assess the outcomes (thyroid ultrasonography, neck scan, whole-body scan, stimulated thyroglobulin, and thyroglobulin antibodies). In the present meta-analysis, both 1100 and 1850 MBq were considered low doses while 3700 was considered a high dose [11]. An example is Kukulska et al [10], whose study was in two stages: first comparing 30 mCi and 60 mCi and in the second, the authors assessed 60 vs 100 mCi and showed no differences.…”

Section: Patientsmentioning

confidence: 86%

“…The current finding is in line with Song et al [4] and Shengguang et al [6] who compared 1.1 GBq and 3.7 GBq; also, the later study restricted its observations to Europe and following incomplete thyroid surgery. A strength of this meta-analysis is that we defined both 1100 and 1850 MBq as a low dose [11]. Besides, we included both thyroxine withdrawal and recombinant TSH for RAI preparation due to the comparable efficacy [22][23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis

Mirghani

Altidlawi

Albalawi

2021

Cureus

View full text Add to dashboard Cite

Radioactive iodine (RAI) is widely used for remnant ablation in low/intermediate differentiated thyroid carcinoma (DTC). However, the optimal effective dose that overweighs the benefits over unwanted side effects is a matter of controversy. This meta-analysis aimed to assess low versus high doses of RAI activity for DTC remnant ablation. Two authors independently searched PubMed and Cochrane Library using the keywords low dose radioactive iodine, high dose radioactive iodine, low-risk/intermediate risk, differentiated thyroid carcinoma, and remnant ablation. Two hundred and twenty references were identified when limiting the engine to controlled trials in English and during the period from January 2010 to December 2020. Nine trials (five from Europe and four from Asia) including 3137 patients fulfilled the inclusion and exclusion criteria. The data were then entered in an extraction sheet detailing the trial information including the author's name, year of publication, country, and type of surgery, preparation for RAI, the patients and control number in the low and high-dose groups, follow-up period, and the results. Out of 220 articles retrieved, nine controlled trials were included (follow-up period range, six months to 12 years, 3137 patients, and low risk of bias). The analysis favored the high dose for remnants ablation, odd ratio, 0.73, 95% CI, 0.50-1.07; P-value for the overall effect was 0.10. However, the results were limited due to the significant heterogeneity observed (56%, P-value 0.03). High-dose RAI was better for DTC remnants ablation. Further studies focusing on intermediate-risk DTC and adjusting for preoperative and postoperative factors are recommended.

show abstract

Section: Patientsmentioning

confidence: 86%